The strong durability and safety profile of TARA-002 in BCG-Naïve NMIBC could de-risk the program and support regulatory path. Focus on completion of BCG-Unresponsive cohort enrollment in 2H 2026 and initiation of ADVANCED-3. Trading on clinical data updates can be volatile; monitor for any financing needs as the company advances toward registrational trials.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $5.10entry
- T+1 · 6mo ago −9.80%α −9.74% · $4.60
- T+5 · 6mo ago −3.53%α −4.49% · $4.92
- T+20 · 5mo ago −22.75%α −24.86% · $3.94
- T+60 · 3mo ago −23.33%α −27.85% · $3.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve NMIBC patients, showing a 72.4% complete response rate at any time, 67% at 6 months, and 55% at 12 months, with no Grade 3+ treatment-related adverse events. The company remains on track to initiate the registrational ADVANCED-3 trial in 2H 2026. These data support TARA-002's potential as a differentiated treatment in a large unmet need market.
Key Facts
- 72.4% complete response (CR) rate at any time in BCG-Naïve NMIBC patients (21/29 evaluable).
- 66.7% CR rate at 6 months and 55.0% CR rate at 12 months.
- No Grade 3 or greater treatment-related adverse events; most TRAEs were Grade 1 and transient.
- Registrational ADVANCED-3 trial planned to initiate in 2H 2026 in BCG-Naïve and potentially BCG-Exposed patients.
- TARA-002 has FDA Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations for certain indications.
Financial Impact
No financial data provided; clinical catalyst only.
Risk Factors
- Clinical trial risks: Phase 2 data may not replicate in larger registrational study.
- Regulatory risks: FDA may require additional data or raise concerns.
- Competitive landscape: existing and pipeline therapies for NMIBC could limit commercial potential.
- Financing risk: Protara may need to raise capital to fund ADVANCED-3 and ongoing operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295716 |
Track record
13 reports on TARA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Viewing Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers